Headlines about Achillion Pharmaceuticals (NASDAQ:ACHN) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Achillion Pharmaceuticals earned a news sentiment score of 0.09 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 45.8846424409376 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the media headlines that may have impacted Accern’s scoring:
- Technical Analysis of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) – The Oracle Examiner (oracleexaminer.com)
- Milacron Holdings Corp. (MCRN) -Analysis about Institutional Investors: Achillion Pharmaceuticals, Inc. (ACHN) – Wallstreet Investorplace (wallstreetinvestorplace.com)
- Achillion Pharmaceuticals, Inc. (ACHN) registers a price change of -0.64% while Puma Biotechnology, Inc. (PBYI … – Stocks Gallery (stocksgallery.com)
- Way to read Technical data on Achillion Pharmaceuticals, Inc. (ACHN) – Wall Street Morning (wallstreetmorning.com)
- In Play Stock Characteristics: Achillion Pharmaceuticals Inc (NASDAQ: ACHN) – Alpha Beta Stock (alphabetastock.com)
A number of research firms recently issued reports on ACHN. Maxim Group set a $7.00 price target on shares of Achillion Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 9th. BidaskClub raised shares of Achillion Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, July 6th. Ladenburg Thalmann Financial Services decreased their price target on shares of Achillion Pharmaceuticals from $9.00 to $6.50 and set a “buy” rating on the stock in a research note on Tuesday, September 12th. Zacks Investment Research raised shares of Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, July 18th. Finally, Robert W. Baird downgraded shares of Achillion Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $5.00 price target on the stock. in a research note on Thursday, August 10th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $6.75.
Achillion Pharmaceuticals (NASDAQ:ACHN) remained flat at $4.59 on Friday. 832,699 shares of the company’s stock were exchanged. The stock has a 50 day moving average of $4.44 and a 200 day moving average of $4.26. The stock’s market cap is $627.74 million. Achillion Pharmaceuticals has a 12 month low of $3.15 and a 12 month high of $7.34.
Achillion Pharmaceuticals (NASDAQ:ACHN) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.16). During the same period last year, the business posted ($0.14) earnings per share. On average, equities analysts expect that Achillion Pharmaceuticals will post ($0.66) EPS for the current year.
WARNING: This piece of content was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://ledgergazette.com/2017/10/15/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-achillion-pharmaceuticals-achn-stock-price.html.
Achillion Pharmaceuticals Company Profile
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.
Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.